Abstract:Purpose: Tumor-specific DNA has recently been detected in the plasma of lung, head and neck, breast, and colon cancer patients. Detection of tumor-specific genetic materials in cancer patients at sites distant from the tumor, such as in the blood, may provide a unique and valuable tumor marker for diagnosis and prognosis.Experimental Design: The present investigation was aimed at determining the presence of p53 mutations in the peripheral blood of breast cancer patients and its prognostic value in these patients.Results: In this study, we found that the mean concentration of plasma DNA in healthy women was 21 ng/ml, whereas in patients with breast cancer the mean concentration was 211 ng/ml (P < 0.01). p53 mutations were detected in the primary tumors of 46 of 126 (36.5%) breast cancer patients. Of these 46 patients, 30 (65.1 %) were found to have p53 mutations in their plasma DNA. p53 mutations in plasma DNA were strongly correlated with clinical stage, tumor size, lymph node (LN) metastasis, and estrogen receptor status (P < 0.05). After a median follow-up of 29 months, univariate and multivariate analysis revealed that both primary tumor and plasma DNA p53 mutations were significant prognostic factors for both relapse-free and overall survival. Furthermore, we demonstrated that patients with both primary tumor and plasma p53 mutations have the worst survival. This outcome occurs in both LN-positive and LN-negative groups. Thirteen of the 22 (59%) patients with recurrence and/or metastasis later had detectable p53 mutations in their plasma DNA.Conclusions: Detection of p53 mutations in plasma DNA may be used as a prognostic factor and an early marker to indicate recurrence or distant metastasis.

Detection of P53 Gene Mutation in Plasma of Patients with Gastric Cancer

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

Application of immunohistochemistry-laser microdissection-PCR technique in detecting p53 gene mutation in paraffin sections of gastric cancer]

The Potential for Serum P53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

Detecting Mutation in Cancer Tissues and Serums of Patients with Gastric Cancer by Denaturing High-Performance Liquid Chromatography

Retracted: P53 Mutation in Plasma Dna and Its Prognostic Value in Breast Cancer Patients (retracted Article. See Vol 8, Pg 3027, 2002)

[Peripheral Blood Mutated P53 DNA and Its Clinical Value in Human Breast Cancer].

Analysis of the P53 Transcriptional Activity in Gastric Cancer

Effects of plasma p53 gene mutation in the development and prognosis of non-small cell lung cancer

Clinical Value of P_53 Gene Mutation in Bladder Cancer

[Detection of P53 Mutation Using PCR-SSCP Silver Staining Method].

[Detection of P53 Gene Mutation in Peripheral Blood in the Diagnosis of Patients with Lung Cancer].

Genetic Mutations of P53 and K-Ras in Gastric Carcinoma Patients from Hunan, China

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study

p53 expression and prognosis in gastric carcinoma

Expression of P53 and PCNA in gastric carcinoma detected by tissue microarray

Research on expressions of P16 and P53 proteins and PCNA in elderly patients with gastric cancer

Detection of P53 Gene Mutations in 14 Tumor Cell Lines

The Clinical Significance of Detection of P53 Gene Mutation in Patients with Lung Cancer